Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Abbott/Adria Oncology Products

Executive Summary

Abbott will market Adria's entire line of multi-source oncology products, including Adriamycin, Adrucil and Folex, to hospitals, wholesalers, and home health care agencies under an agreement announced Nov. 16. Adria, a division of Erbamont, will continue to sell the products to oncology clinics, physicians offices, and oncology wholesalers. Adria hopes to take advantage of Abbott's large sales force to protect Adriamycin (doxorubicin HCl) from generic competition from Bristol-Myers Squibb's Rubex and Cetus-Ben Venue's Doxorubicin HCl. A press release issued by the two companies calls Abbott the U.S. "market leader in multi-source hospital injectable products." The two companies also announced that they "have agreed to jointly develop drug delivery systems for the reconstitution and delivery of chemotherapeutic agents." Adria indicated that the two companies would work to modify existing Abbott drug delivery systems (especially the ADD-Vantage I.V. system) to suit Adria's oncology products.

You may also be interested in...

Shuren: CDRH Writing Guidance To Explain What Should Happen To All Those EUA Tests, Devices

Jeff Shuren, director of the US FDA’s device center, says the agency is working on a draft guidance document that will give industry recommendations on how it should handle products granted emergency use authorization during the COVID-19 public health emergency. The guidance will also address already-approved devices that were modified by their makers under enforcement discretion.

ESMO: Merck Sees Keytruda-Lenvima Potential In Melanoma, Hard-To-Treat Cancers

Keytruda-Lenvima picked out as pick of combination therapies from the European cancer congress.

Not Too Late? German Industry Presses For EU MRA With Post-Brexit UK

BVMed says the EU and the UK should set up a system of mutual recognition of medical device regulation to kick in when the UK’s EU exit transition period ends on 31 December. 




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts